Sarepta’s Exondys 51 Successor On Clinical Hold, But Quick Resolution Expected
Executive Summary
The FDA placed a hold on the Phase II study of SRP-5051, which uses the company’s next-generation peptide conjugation technology, but Sarepta thinks it can address safety questions in short order.
You may also be interested in...
Sarepta Leapfrogs Pfizer In The US, Launching DMD Gene Therapy Pivotal Trial
The company has initiated the first pivotal double-blind gene therapy trial in DMD in the US in a tight race with Pfizer.
Sarepta’s Next-Gen DMD Drug SRP-5051 Shows Advantages, But Safety Concerns Too
The next-generation DMD drug showed dramatic improvement on exon dystrophin and exon skipping, but small numbers and adverse events give pause.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.